期刊文献+

大鼠肝脏隔离灌注不同剂量5-氟脲嘧啶静脉血中前列环素与血栓素A_2的变化 被引量:3

The changes of thromboxane B2 and 6-ke-to-PGF 1α in vein blood during isolated liverperfusion with different doses 5-Fu in rats
原文传递
导出
摘要 应用大鼠肝脏隔离灌注模型,以不同剂量5-氟脲嘧啶(5-Fu)行门静脉灌注,用放免法检测下腔静脉血中TXB_2与6-keto-PGF_(1α)水平,结果表明,ILP5-Fu300mg/kg组术后3天TXB_2明显升高,6-keto-PGF_(1α)升高不显著;ILP5-Fu150mg/kg组与灌注平衡液组TXB_2比术前明显升高,但两组间无明显变化,6-keto-PGF_(1α)与术前相比无明显变化。在ILP5-Fu300mg/kg组,TXB_2/6-keto-PGF_(1α)值与GPT值呈正相关。提示TXA_2与PGI_2平衡的改变与超MTD的5-FuILP时肝组织损伤密切相关。 This papar presents that thromboxane B2(TXB2) and 6-keto-PGF1α levels in the bloodof inferior vena cava were determined by ra-dioimmunoassay method by means of isolatedliver perfusion(ILP)model with different dos-es 5-Fu through portal vein route in rats.Theresults showed that TXB2 levels were signifi-cantly increased and 6-keto-PGF 1α levels notincreased in group of ILP with 300mg/kg 5-Fuat the third postoperative day.TXB2 levels ingroups of ILP with 150mg/kg 5-Fu and with-out 5-Fu were higher than preoperative levelsand TXB2 levels between these two groupsunchanged.The 6-keto-PGF1α levels have noapparent changes as compared with preopera-tive levels。There was a high positive relativityin TXB2/6-keto-PGF1αratios and SGPT ingroup of ILP with 300mg/kg 5-Fu.The re-sults indicated that the imbalance between lev-els of TXB2 and 6-keto-PGF1α was associatedwith hepatic injuries during ILP with overthan MTD5-Fu.
作者 邢雪 夏穗生
出处 《中华实验外科杂志》 CSCD 北大核心 1995年第3期159-160,共2页 Chinese Journal of Experimental Surgery
关键词 隔离灌注 氟脲嘧啶 前列环素 血栓素 肝肿瘤 ILP 5-Fu TXB_2 6-keto-PGF1α hepatic injury
  • 相关文献

同被引文献11

  • 1梁浩晖,何劲松,王先明,郭良峰,周汝明,邱水波,王成友.经皮选择性肝脏隔离灌注化疗方法学研究[J].广东医学,2004,25(8):881-883. 被引量:4
  • 2叶坚,梁浩晖,何劲松,王成友,王先明,周汝明,邱水波,钱文璟.新型双球囊导管经皮选择性隔离肝脏灌注化疗的效果研究[J].岭南现代临床外科,2007,7(3):169-170. 被引量:1
  • 3Ku Y, Tominaga M, LwasakiT,et al. Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors. Int J Clin Oncol,2002,7(1):82.
  • 4Creech JO, Krementz ET, Winblad JN. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg, 1958, 148:616-632.
  • 5Ku Y ,Tominaga M ,Iwasaki T, et al. Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors. Int J Clin Oncol, 2002,7:82-90.
  • 6Gavriel Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. Cell Biol, 1992,119:493-501.
  • 7Creech JO,Krementz ET,Winblad JN,Chemotherapy of cancer:Regional perfusion utilizing an extracorporeal circuit[J].Ann Surg,1958,148(2):616-632.
  • 8Ku Y,Tominaga M,Iwasaki T,et al.Isolated hepatic perfusion chemo-therapy for unresectable malignant hepatic tumors[J].Int J Clin Oncol,2002,7(1):82-90.
  • 9Gavriel Y,Sherman Y,Ben-Sasson SA.Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation[J].Cell Biol,1992,119(2):493-501.
  • 10Ku Y,Iwasaki T,Fukomoto T,et al.Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion[J].Ann Surg,1998,227(2):519-526.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部